Personalized urooncology based on molecular uropathology: What is the future? Personalisierte Uroonkologie auf der Grundlage einer molekularen Uropathologie: Was ist die Zukunft?
Dahl E, Haller F (2013)
Publication Type: Journal article
Publication year: 2013
Journal
Book Volume: 52
Pages Range: 976-981
Journal Issue: 7
DOI: 10.1007/s00120-013-3229-y
Abstract
Targeted therapies and biomarker validation are key drivers in the advancement of personalized oncology which is a growing topic in all clinical areas. Compared with other professions, such as pulmonology and gynecology, development in urology has so far been retarded but has recently gained increasing momentum. A basis for this is the currently growing and in future accelerated application of new knowledge derived from molecular biology in the field of uropathology. The rapid gain of knowledge is driven by a whole new class of analytical methods, such as massively parallel sequencing (deep sequencing or next generation sequencing), which enables analysis of virtually a new universe of potential biomarkers. This article describes the emerging paradigm shift in molecular pathological diagnostics of urological tumors using the example of prostate cancer. © 2013 Springer-Verlag Berlin Heidelberg.
Authors with CRIS profile
Involved external institutions
Germany (DE)How to cite
APA:
Dahl, E., & Haller, F. (2013). Personalized urooncology based on molecular uropathology: What is the future? Personalisierte Uroonkologie auf der Grundlage einer molekularen Uropathologie: Was ist die Zukunft? Urologe, 52(7), 976-981. https://doi.org/10.1007/s00120-013-3229-y
MLA:
Dahl, E., and Florian Haller. "Personalized urooncology based on molecular uropathology: What is the future? Personalisierte Uroonkologie auf der Grundlage einer molekularen Uropathologie: Was ist die Zukunft?" Urologe 52.7 (2013): 976-981.
BibTeX: Download